NCT02841774View on ClinicalTrials.gov

High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
HIV InfectionCoronary Heart Disease
Interventions
DRUG

Pravastatin

40mg daily (Weeks 2 - 14)

DRUG

Rosuvastatin

20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK \<+1.5 x ULN, and LDL-c is \>60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
lead

Matthew Feinstein

OTHER

NCT02841774 - High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV | Biotech Hunter | Biotech Hunter